News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Go-ahead for PledPharma to also include Avastin patients in Part 2 of the PLIANT study

April 23, 2014

PledPharma AB
Company Announcement

Go-ahead for PledPharma to also include Avastin patients in Part 2 of the
PLIANT study

Stockholm, 2014-04-23 08:30 CEST (GLOBE NEWSWIRE) -- 

PledPharma has received approval from the DSMB (Drug Safety Monitoring Board,
an independent panel of experts) to also include patients being treated with a
combination of FOLFOX and Avastin (bevacizumab) in the randomized part of the
Phase IIb study PLIANT. 

The approval comes after the DSMB has analyzed the data from the first three
patients enrolled in the study with this combination. Bevacizumab is commonly
used in cancer treatment and the combination FOLFOX / bevacizumab can now be
used at all centers in the PLIANT study. 

For further information, please contact:

Jacques Näsström, CEO

+46 737 13 09 79

Michaela Gertz, CFO

+46 709 26 17 75

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new therapies for
the treatment of life threatening diseases. The initial objective is to develop
a drug, PledOx®, which reduces severe side-effects associated with
chemotherapy. The current market for supportive cancer care is some USD 10
billion. PledPharma also evaluates an existing medicines possibility to reduce
the damage that occurs on the heart muscle when patients suffer from acute
myocardial infarction. In addition to these projects, the company is also
evaluating opportunities of using our technology platform in additional areas
where there is a significant unmet medical need. PledPharma has the potential
to offer patients valuable and unique treatments for serious life-threatening
diseases where there is an opportunity fast registration in the US through
"breakthrough therapy" designation. This means that the company has the
potential to offer shareholders a good return on their investment. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10